185 results on '"Munakata, Wataru"'
Search Results
2. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma
3. Interim PET‐guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced‐stage classic Hodgkin lymphoma (JCOG1305).
4. The Association between Gut Microbiota and Depression in the Japanese Population
5. An update on the developments in the treatment of adult T-cell leukemia–lymphoma: current knowledge and future perspective
6. P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE
7. P1520: PROGNOSTIC IMPACT OF FEBRILE NEUTROPENIA AND DOSE INTENSITY OF R-CHOP THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, A SUPPLEMENTARY ANALYSIS OF JCOG0601
8. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma
9. Variegated RHOA mutations in adult T-cell leukemia/lymphoma
10. Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
11. Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)
12. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers
13. SY08-2 The development of BCR signaling pathway-targeted therapy for B-cell malignancies
14. Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia
15. The outcome of watchful waiting in patients with previously treated follicular lymphoma
16. The role of surveillance computed tomography in patients with follicular lymphoma
17. Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia
18. Impact of Progression-Free Survival at 24 Months on Subsequent Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP Therapy: A Supplementary Analysis of JCOG0601
19. Clinicopathological features of classical Hodgkin lymphoma in patients ≥40 years old, with special reference to composite cases
20. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
21. Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
22. Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1)
23. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
24. Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy
25. Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma
26. A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia
27. COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma
28. Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin
29. Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia
30. Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma
31. Rare Cancer Center - All Activities for Rare Cancer Patients! -
32. Meet the Expert on Rare Cancer - Social Contribution by Rare Cancer Center -
33. Revised staging system for malignant lymphoma based on the Lugano classification
34. Phase I study of tirabrutinib (ONO‐4059/GS‐4059) in patients with relapsed or refractory B‐cell malignancies in Japan
35. Genomics of Limited-Stage Diffuse Large B-Cell Lymphoma Developing Late Relapse: Analysis of Gene Alterations in Paired Primary and Late Relapsed Tumors By Target Sequencing
36. Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab
37. Phase I study of glasdegib (PF‐04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies
38. Childhood, adolescent and young adult cancer incidence in Japan in 2009–2011
39. Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome
40. The Prognostic Impact of Relative Dose Intensity of Vincristine in R-CHOP for Untreated Patients with Diffuse Large B-Cell Lymphoma: A Supplementary Analysis of JCOG0601
41. PD5-4 - Rare Cancer Center - All Activities for Rare Cancer Patients! -
42. MO1-4-2 - Meet the Expert on Rare Cancer - Social Contribution by Rare Cancer Center -
43. Disseminated herpes zoster infection initially presenting with abdominal pain in patients with lymphoma undergoing conventional chemotherapy: A report of three cases
44. Cross-Sectional Patient Survey on the Need for a Long-Term Follow-up Program after Autologous Hematopoietic Cell Transplantation
45. FUS-ERGgene fusion in isolated myeloid sarcoma showing uncommon clinical features
46. Role of FDG-PET/CT in the Staging of Patients with Follicular Lymphoma
47. Next-Generation Sequencing Reveal Proviral Genome and Transcriptome in Adult T-Cell Leukemia/Lymphoma
48. Prognostic Relevance of Integrated Genetic Profiling in Adult T-Cell Leukemia/Lymphoma
49. Frequent Activating Somatic Alterations in T-Cell Receptor / NF-κb Signaling in Adult T-Cell Leukemia/Lymphoma
50. A phase I b study of panobinostat and 5-azacitidine in Japanese patients with MDS, CMML, or AML
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.